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Introduction
Steroid hormones are essential for normal develop-
ment and stress responses. Corticosteroids bind to and
activate the cytoplasmic glucocorticoid receptor (GR),
a widely expressed steroid hormone receptor (1). In the
classic model of steroid hormone action, GR acts as a
ligand-dependent transcription factor by either acti-
vating or repressing gene expression through direct
interactions with DNA or other transcription factors
(2). The actions of GR are essential for survival. Mice
lacking GR (GR–/–) die at birth (3); in contrast, overex-
pression of GR renders mice resistant to stress and
endotoxic shock (4). Although the absence of GR is
incompatible with life, DNA binding and transactiva-
tion of target genes by GR is not essential for develop-
ment or survival, since mice with a targeted mutation
in the dimerization domain of GR (GRdim), which
impairs cooperative DNA binding and transactivation
by GR homodimers, lack GR-dependent gene expres-
sion but survive to adulthood (5).
Some effects of corticosteroids on the brain and vas-
cular system are very rapid, which makes transcrip-
tional mechanisms of action unlikely. For example,
behavioral changes in amphibians and increases of
inositol trisphosphate in vascular smooth-muscle cells
occur within minutes of corticosteroid administration
(6, 7). Furthermore, the acute, antianaphylactic effects
of high-dose corticosteroids in mice are unaltered by
the transcriptional inhibitor actinomycin D (8). Thus,
GR may exert important nontranscriptional functions.
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Many cellular responses to corticosteroids involve the transcriptional modulation of target genes by the
glucocorticoid receptor (GR). A rapid, non-nuclear effect of GR was found to mediate neuroprotection.
High-dose corticosteroids (20 mg/kg intraperitoneally), given within 2 hours of transient cerebral
ischemia, acutely increased endothelial nitric oxide synthase (eNOS) activity, augmented regional cere-
bral blood flow (CBF) by 40% to 50%, and reduced cerebral infarct size by 32%. These neuroprotective
effects of corticosteroids were abolished by the GR antagonist RU486 and by inhibition of phos-
phatidylinositol 3-kinase (PI3K), and were absent in eNOS–/– mice. To determine the mechanism by which
GR activated eNOS, we measured the effect of corticosteroids on PI3K and the protein kinase Akt. In a
ligand-dependent manner, GR activated PI3K and Akt in vitro and in vivo caused NO-dependent vasodi-
lation, which was blocked by cotreatment with RU486 or the PI3K inhibitor LY294002 but not by tran-
scriptional inhibitors. Indeed, a mutant GR, which cannot dimerize and bind to DNA, still activated PI3K
and Akt in response to corticosteroids. These findings indicate that non-nuclear GR rapidly activates
eNOS through the PI3K/Akt pathway and suggest that this mechanism mediates the acute neuropro-
tective effects of corticosteroids through augmentation of CBF.
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There is growing evidence that nontranscriptional
actions of steroid hormone receptors regulate physio-
logically important processes. For example, osteocyte
apoptosis is regulated by the androgen and estrogen
steroid receptors through nontranscriptional activa-
tion of Src and mitogen-activated protein kinase
(MAPK) (9). Vascular nitric oxide (NO) production and
vasodilation by estrogen depend on nontranscription-
al activation of endothelial NO synthase (eNOS) and
are mediated by estrogen receptor α–dependent (ERα)-
dependent activation of the phosphatidylinositol 
3-kinase (PI3K)/Akt pathway (10–12). It is important
to note that the vascular protective effects of estrogen
are dependent on the nontranscriptional activation of
eNOS through the PI3K/Akt pathway (11).
Endothelial-derived NO is a critical mediator of vas-
cular integrity. Vascular NO production regulates
cerebrovascular perfusion and protects against stroke
by increasing collateral flow to the ischemic area (13).
Mice lacking eNOS exhibit larger cerebral infarctions
(14), and further inhibition of NOS activity by Nω-
nitro-L-arginine methyl ester (L-NAME) decreases cere-
bral blood flow (CBF) and increases infarct size after
ischemia in mice lacking neuronal nitric oxide syn-
thase (nNOS) (15). In contrast, enhanced NO produc-
tion by administration of the eNOS substrate, L-argi-
nine, or upregulation of eNOS by statins confer
protection from stroke (16, 17). Therefore, conditions
that enhance eNOS activity could have beneficial
effects on cerebrovascular disease.
Corticosteroids have been used in the treatment of
stroke with conflicting results (18). Some clinical and
experimental data, however, suggest a beneficial role
for these steroids in reducing ischemic tissue injury.
Corticosteroids reduce ischemic injury in myocardial
infarction (19) and substantially reduce stroke size in
focal cerebral ischemia (20–22). Indeed, we have recent-
ly shown that the anti-inflammatory and myocardial
protective effects of acute steroid therapy are mediated
by nontranscriptional activation of eNOS through the
PI3K/Akt pathway (23). However, long-term corticos-
teroid therapy may be associated with an increased risk
of stroke, due in part to transcriptional downregula-
tion of eNOS expression and an increase in systemic
blood pressure (24). The mechanism of stroke protec-
tion by steroids, therefore, is essentially unknown.
Here, we examine whether non-nuclear signaling by GR
could contribute to neuroprotection by a novel mech-
anism involving an increase in CBF.
Methods
Cells and reagents. Human endothelial cells were main-
tained in EGM-2 growth medium (Clonetics, San
Diego, California, USA) and used at the third passage.
Bovine aortic endothelial cells (BAECs) and COS7 cells
were grown in DMEM (Life Technologies Gibco BRL,
Grand Island, New York, USA) with 10% FCS. For
experiments, cells were cultured for 48 hours in phenol
red–free medium with charcoal-stripped FCS, and this
procedure was followed by serum-starvation. Cells were
incubated with dexamethasone (Sigma-Aldrich, St.
Louis, Missouri, USA), RU486 (Biomol, Plymouth
Meeting, Pennsylvania, USA), actinomycin D,
LY294002 (Calbiochem, San Diego, California), or
vehicle (DMSO). Phosphatidylinositol 4,5-bisphos-
phate was purchased from Biomol and [32P]γATP from
New England Nuclear Life Science Products (Boston,
Massachusetts, USA). The following antibodies were
used: GR (rabbit, Santa Cruz Biotechnology, Santa
Cruz, California, USA; mouse, Transduction Laborato-
ries, Lexington, Kentucky, USA); MR (rabbit and goat,
Santa Cruz Biotech); ERα (rabbit, Santa Cruz Biotech;
mouse, Neomarkers, Freemont, California, USA); p85α
(rabbit, Upstate Biotechnology, Lake Placid, New York,
USA; mouse, Transduction Laboratories); P-Akt and
Akt (rabbit, Cell Signaling Technology, Beverly, Mass-
achusetts, USA); P-Tyr 4G10 (mouse, Upstate Biotech-
nology); eNOS (mouse, Transduction Labs); actin (rab-
bit, Sigma-Aldrich). All other reagents were purchased
from Sigma-Aldrich.
PI3K assay. Approximately 500 µg of protein in buffer
A (1% NP-40, 20 mM Tris [pH 7.4], 137 mM NaCl, 1
mM CaCl2, 1 mM MgCl2, 0.1 mM Na3VO4) were incu-
bated with 1 µg of GR antibody and immunoprecipi-
tated with 40 µl of 1:1 protein A/agarose. PI3K activity
in the immunoprecipitate was assayed as described
(25). The phospholipids were extracted with 160 µl of
chloroform/methanol (1:1, v/v) and separated by
borate thin-layer chromatography.
Akt kinase assay and Western blotting. Cells or tissues were
homogenized in lysis buffer (1% Triton, 20 mM Tris [pH
7.4], 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2.5 mM
sodium pyrophosphate, 1 mM β-glycerolphosphate, 1
mM Na3VO4), and Akt kinase activity was determined
by detection of phosphorylated GSK-3 fusion protein
using the Akt kinase assay kit (Cell Signaling Technol-
ogy) according to the manufacturer’s guidelines. For
Western blotting of cell extracts, typically 25–40 µg of
protein were separated by SDS-PAGE, transferred to
nitrocellulose membranes (Osmonics, Westborough,
Massachusetts, USA), and probed with antibodies
according to the manufacturer’s instructions.
Transient transfection and reporter assays. BAECs were
transfected for 6 hours with 8 µg of pGRE-Luc (Clon-
tech, Palo Alto, California, USA) and Lipofectamine
2000 reagent (Invitrogen, Carlsbad, California, USA) at
a ratio of 3:1. COS7 cells were transfected with 0.1 µg
of expression plasmid and 0.4 µg of GRE-Luc using the
Fugene 6 Transfection Reagent (Roche Molecular
Diagnostics, Mannheim, Germany) at a ratio of 3:1. In
all conditions, pCMV β-galactosidase was cotransfect-
ed, luciferase and β-galactosidase activity was deter-
mined with the Dual-Light kit (Tropix, Bedford, Mass-
achusetts, USA), and luciferase activity was normalized
to β-galactosidase activity.
eNOS activity assay and cGMP measurement. eNOS activ-
ity was determined by measuring the conversion of
[3H]L-arginine to [3H]L-citrulline in the presence or
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absence of the competitive NOS inhibitor L-NAME (1
mM) using an NOS assay kit (Calbiochem-Nov-
abiochem). Mouse aortae were homogenized in ice-cold
PBS containing 1 mM EDTA, the homogenates were
pelleted, and 5 µg of protein extracts from the super-
natant were used for the eNOS assay as described (17).
Unlabeled L-arginine was added to [3H]L-arginine (spe-
cific activity, 60 Ci/mmol) at a ratio of 3:1. For meas-
urement of intracellular cGMP (26), cells were pretreat-
ed with 0.5 mM isobutylmethylxanthine for 15 minutes,
and proteins were extracted with 0.1 N HCl and ana-
lyzed with a cGMP radioimmunoassay kit (Amersham
International, Little Chalfont, United Kingdom).
Real-time PCR. Total RNA isolation and reverse tran-
scription from ischemic regions were performed as
described (27). Real-time PCR was conducted using
Biorad iCycler (iCycler iQ Multi-Color Real Time PCR
Detection System; Biorad, Hercules, California, USA).
The following primer pairs were used: mouse eNOS (5′-
TTCCGGCTGCCACCTGATCCTAA-3′ forward and 5′-
AACATGTGTCCTTGCTCGAGGCA-3′ reverse) and mouse
GAPDH (5′-GAGAATGGGAAGCTTGTCATC-3′ forward
and 5′-GTCCACCACCCTGTTGCTGTA-3′ reverse). The
fluorescence of Cyber green (PE Biosystems, Foster City,
California, USA) was used for quantitation of ampli-
cons. The PCR conditions for eNOS were 95°C (13:30
minutes), 94°C (5:00 minutes), and then 34 cycles of
94°C (40 seconds), 60°C (1:20 minutes), and 72°C
(1:20 minutes), followed by 88°C (15 seconds) for data
collection. The PCR conditions for GAPDH were 95°C
(13:30 minutes), 94°C (5:00 minutes), and then 23
cycles of 94°C (1 minute), 62°C (2:00 minutes), and
72°C (2:30 minutes), followed by 83°C (15 seconds) for
data collection. The relative amount of eNOS cDNA
was calculated by reference to the GAPDH cDNA in the
sample using the Ct method (ABI PRISM 7700
Sequence Detection System; Applied Biosystems, Fos-
ter City, California, USA) and then compared with the
amount at the 0 time point. Ct is the point at which the
exponential increase in signal (fluorescence) crosses a
somewhat arbitrary signal level (usually 10 times back-
ground) and is related to the copy number by 2–Ct.
Vascular ring bioassay. Wall tension was measured as
described (28). Briefly, isolated aortae were cut into
rings (1.5–2 mm) and mounted on an isometric myo-
graph (610M, Danish Myo Technology, Aarhus, Den-
mark) in physiological solution (118 mM NaCl, 4.6
mM KCl, 25 mM NaHCO3, 1.2 mM MgSO4, 1.2 mM
KH2PO4, 1.25 mM CaCl2, 10 mM glucose, 0.025 mM
EDTA) at 37°C with or without dexamethasone for 60
minutes. After equilibration, contractile responses were
recorded using a data-acquisition and —recording soft-
ware (Myodaq and Myodata, Danish Myo Technology).
Transient middle-cerebral-artery occlusion. All experi-
ments were conducted in accordance with National
Institute of Health and Massachusetts General Hospi-
tal institutional guidelines. The left middle cerebral
artery of male SV-129 (Taconic, Germantown, New
York, USA) or eNOS–/– mice was occluded for 2 hours by
advancing an 8-0 nylon silicone-coated monofilament
10 mm distal to the carotid bifurcation as described
(14). The infarcted areas were measured on brain sec-
tions stained with 2,3,5-triphenyltetrazolium (TTC; 24
hours) or on hematoxylin and eosin–stained cryostat
sections (72 hours) with an image-analysis system (Bio-
quant IV, R&M Biometrics, Nashville, Tennessee, USA)
and were quantitated by summing the volumes of each
section. In some experiments, infarct volume was cor-
rected for edema (29). Regional CBF was determined by
laser Doppler flowmetry (Perimed PF2B, Stockholm,
Sweden) and recorded on a MacLab/8 data acquisition
system (AD Instruments, Milford, Massachusetts, USA)
as described previously. Serum dexamethasone levels
were determined by Quest Diagnostics Inc (San Juan
Capistrano, California, USA).
CBF measurement. Regional CBF was quantified using
the [14C]iodoantipyrine autoradiography technique as
described previously (30). Isoflurane-anesthetized mice
received [14C]iodoantipyrine (5 µCi in 100 µl saline) for
1 minute by infusion. Arterial blood samples were col-
lected at 5-second intervals onto preweighed filter
paper disks and measured by liquid scintillation spec-
trometry (RackBeta 1209; Pharmacia-Wallac, Gaithers-
burg, Maryland, USA). Immediately after decapitation,
the whole head was immersed in chilled isopentane
over dry ice (–45°C), and then the frozen brains were
sectioned coronally (20 µm). The sections were thaw-
mounted on glass coverslips, dried (60°C), and exposed
to autoradiography along with [14C]polymer standards
(Amersham Life Sciences Inc.). In some experiments,
CBF was determined using the indicator fractionation
technique with N-isopropyl-[methyl 1,3-14C]-p-iodo-
amphetamine as described previously (17).
Statistics. The difference in cerebral infarct volume was
analyzed by one-way ANOVA followed by Duncan’s test.
CBF and ring experiments were analyzed by two-way
ANOVA followed by t-test or Tukey test, respectively. Stu-
dent’s t test was used for all other analyses. All values are
expressed as means ± SEM unless otherwise indicated.
Results
Acute neuroprotective effects of corticosteroids mediated by
eNOS. To determine whether acute administration of
corticosteroids protects against ischemic stroke, mice
were treated with the synthetic corticosteroid dexa-
methasone and subjected to transient middle cerebral-
artery occlusion (MCAo). In a dose-dependent manner,
dexamethasone treatment 1 hour before and 2 hours
after MCAo decreased cerebral infarct volume by 32%
as compared with vehicle treatment (74 ± 8 mm3 vs.
108 ± 9 mm3, P < 0.05). The reduction in stroke volume
by dexamethasone was evident up to 3 days after
ischemia, suggesting sustained neuroprotection by cor-
ticosteroids (Figure 1a).
To evaluate neuroprotection by corticosteroids after
the onset of ischemia, we compared the efficacy of dif-
ferent treatment regimens to reduce stroke size
(schema in Figure 1b). The standard regimen was com-
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pared to a single bolus injection of dexamethasone 2 or
4 hours after the onset of ischemia. Administration of
dexamethasone up to 2 hours after the onset of
ischemia reduced stroke volume by 25% as compared
with the vehicle group (84 ± 7 mm3 vs. 112 ± 8 mm3, 
P < 0.05), an effect that was lost when treatment was
initiated 4 hours after MCAo (Figure 1b). Thus, corti-
costeroids rapidly confer neuroprotection when
administered early after the onset of ischemia.
Reduction in myocardial infarct size by steroids
involves the nontranscriptional activation of eNOS (23).
To test whether eNOS mediates the acute cerebrovascu-
lar protective effect of dexamethasone, cerebral infarct
volume was evaluated in mice with a targeted disruption
of the eNOS gene (eNOS–/–) (31). In contrast to the wild-
type mice treated with high-dose steroids, eNOS–/– mice
treated with dexamethasone showed no reduction in
stroke size (reduction, 4% ± 10%; P > 0.05) after transient
ischemia (Figure 1c), whereas physiological parameters
were comparable (data not shown). These findings indi-
cate that eNOS mediates the acute neuropro-
tective effects of corticosteroids. Although
eNOS is required for neuroprotection by
steroids, eNOS mRNA and protein levels in
brain tissues were unchanged in vivo, suggest-
ing a nontranscriptional mechanism of eNOS
enhancement (Figure 1d).
Corticosteroids have been thought to ame-
liorate ischemic tissue damage by reducing
associated brain edema (18). Nevertheless,
when stroke volume was corrected for brain
edema (29), the protective effect of dexametha-
sone was sustained (65 ± 8 mm3 vs. 92 ± 7 mm3,
n = 11, P < 0.05), indicating that corticosteroids
protected against cerebral injury (Figure 1c). It
is interesting to note that we also found an
eNOS-dependent effect of steroids on edema
formation. Dexamethasone reduced cerebral
edema by 37% in the eNOS–/– mice as compared
with 72% in the wild-type strain (17± 3 mm3
[n = 10] vs. 5 ±1 mm3 [n = 11], P < 0.05).
Corticosteroids enhance NO-dependent CBF. Be-
cause cerebral infarct size is inversely related to
CBF, and endothelium-derived NO regulates
cerebral vascular tone and CBF (32), we exam-
ined whether corticosteroids can enhance
regional CBF to ischemic areas of the brain.
Mice were subjected to transient MCAo and
regional intraischemic CBF was determined
using [14C]iodoantipyrine autoradiography.
After MCAo, there was little or no blood flow in
the cortical and subcortical parietal lobe of vehi-
cle-treated mice. In mice treated with dexa-
methasone, the entire core infarct zone appeared
smaller, and blood flow was substantially high-
er in the core region, particularly in the caudate
putamen and in the adjacent peri-ischemic areas
(Figure 2a). These findings demonstrate that
corticosteroids can enhance intraischemic CBF.
To confirm that corticosteroids augment regional
CBF, absolute CBF was quantified by [14C]iodoan-
tipyrine measurement. Within 1 hour, treatment with
dexamethasone increased absolute CBF in the core
ischemic zone (caudate putamen and thalamus) and the
penumbral areas (Figure 2b). It is interesting to note that
corticosteroids also enhanced CBF in nonischemic areas
of the brain. Since equal percentages of ischemia
between treatment groups were confirmed by laser
Doppler flowmetry (Table 1 and Methods), this demon-
strates a beneficial effect of corticosteroids on absolute
ischemic CBF. In addition, it provides evidence that
enhancement of cerebral perfusion by steroids occurs
rapidly, suggesting a nongenomic mechanism of action.
Indeed, the increase in CBF by corticosteroids was medi-
ated by NO, since no augmentation of CBF was observed
in either the ischemic or nonischemic hemispheres after
MCAo in eNOS–/– mice (Figure 2c).
Nontranscriptional activation of PI3K mediates stroke protec-
tion by corticosteroids. Endothelial NO release is enhanced
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Figure 1
Acute neuroprotection by corticosteroids requires eNOS. (a) Dose–dependent
effects of dexamethasone (Dex) on stroke volume derived from TTC-stained (24
hours) or hematoxylin and eosin–stained (72 hours) brain sections after MCAo
(n = 8–11). *P < 0.05 vs. vehicle. (b) Effects of delayed steroid treatment on neu-
roprotection. Shown is a schema of treatment regimens and corresponding
cerebral infarct reduction by dexamethasone relative to the vehicle (Veh) group
(n = 7–11). *P < 0.05 vs. vehicle. (c) Infarct volume corrected for edema in wild-
type and eNOS–/– mice treated with vehicle or dexamethasone (20 mg/kg bolus
administered intraperitoneally [i.p.]) 24 hours after MCAo (n = 5–11). Wild-
type mice are identical to those in (a). *P < 0.05 vs. all other groups; WT, wild-
type. (d) The eNOS protein and mRNA levels after steroid treatment. Equal
amounts of aortic tissue homogenates (40 µg) were immunoblotted against
eNOS followed by stripping and reprobing against actin (top panels). A repre-
sentative experiment is shown. Three separate experiments yielded similar
results. Brain eNOS mRNA expression from mice treated with vehicle or dex-
amethasone with or without RU486 (RU) or LY294002 (LY) for 24 hours is
shown in the lower panel. The corrected eNOS mRNA levels (eNOS/GAPDH)
were determined by real time PCR (n ≥ 3 for each condition). t, time.
through direct phosphorylation of eNOS by the protein
kinase Akt downstream of PI3K (33, 34). We have previ-
ously shown that GR activates eNOS through the
PI3K/Akt pathway in a nontranscriptional fashion (23).
To determine whether rapid GR signaling to PI3K medi-
ates neuroprotection by steroids, we evaluated cerebral
infarct volume with the PI3K inhibitor, LY294002, and
the GR antagonist RU486. As compared with the high-
dose treatment group, LY294002 and RU486 both
reversed the beneficial effects of dexamethasone on cere-
bral infarct volume without altering baseline values, sug-
gesting that neuroprotection is mediated by PI3K and
GR (Figure 3a). Comparison of physiological parameters,
mortality, and serum dexamethasone levels after treat-
ment revealed no significant difference between treat-
ment groups (Table 1).
Class I PI3K catalyzes the formation of 3′-phosphory-
lated phosphatidylinositols (e.g., phosphatidylinositol
3,4,5-trisphosphate [PIP3]) from phosphatidylinositol
phosphate precursors (35). This leads to the subsequent
recruitment and activation of protein kinase Akt (36).
To evaluate the rapid signaling mechanisms initiated by
GR in vivo, we measured GR-associated PI3K activity
from brains of dexamethasone-treated mice. Dexa-
methasone treatment leads to a rapid increase in PI3K
activity, as measured by the generation of PIP3. GR-asso-
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Figure 2
Regulation of CBF by corticosteroids.(a) 
Representative pseudocolor image of CBF
([14C]iodoantipyrine autoradiography) from
coronal brain sections 1 hour after MCAo in
mice treated with dexamethasone (20 mg/kg)
or vehicle. (b) Regional changes in absolute
CBF ([14C]iodoantipyrine) in ipsilateral and
contralateral brain areas of mice treated with
dexamethasone (20 mg/kg administered
intraperitoneally) or vehicle (n = 10 per group).
(c) Changes in absolute CBF in eNOS–/– mice
were determined by the [14C]iodoampheta-
mine technique and expressed as percentages
of contralateral CBF of vehicle-treated mice.
*P < 0.05 vs. vehicle.
Table 1
Effects of high-dose corticosteroids on SV-129 mice
Vehicle Dex Dex + RU Dex + LY
MABP (mm Hg) Pre 106 ± 112 112 ± 12 109 ± 11 102 ± 10
MCAo 104 ± 11 107 ± 11 105 ± 9 98 ± 12
Post 99 ± 8 100 ± 10 98 ± 10 101 ± 18
CBF (%) Pre 100 ± 0 100 ± 0 100 ± 0 100 ± 0
MCAo 10 ± 4 8 ± 4 12 ± 5 15 ± 8
Post 103 ± 17 107 ± 24 102 ± 19 97 ± 18
pH (arterial) Pre 7.32 ± 0.04 7.32 ± 0.02 7.37 ± 0.03 7.31 ± 0.02
MCAo 7.33 ± 0.04 7.32 ± 0.03 7.35 ± 0.04 7.35 ± 0.02
Post 7.33 ± 0.02 7.32 ± 0.03 7.36 ± 0.04 7.32 ± 0.03
paCO2 (mm Hg) Pre 39.6 ± 5.1 41.4 ± 4.2 42.3 ± 6.1 42.3 ± 5.6
MCAo 40.4 ± 6.9 41.7 ± 5.6 41.5 ± 4.9 41.7 ± 4.6
Post 41.0 ± 4.1 43.4 ± 2.7 43.6 ± 3.0 39.4 ± 4.5
paO2 (mm Hg) Pre 136 ± 16 136 ± 19 129 ± 17 124 ± 13
MCAo 143 ± 12 137 ± 12 145 ± 15 125 ± 14
Post 137 ± 8 128 ± 10 135 ± 11 128 ± 15
RT (°C) Pre 36.9 ± 0.2 36.7 ± 0.4 37.2 ± 0.3 36.7 ± 0.2
MCAo 36.7 ± 0.4 36.8 ± 0.4 36.8 ± 0.4 37.1 ± 0.4
Post 36.5 ± 0.3 36.8 ± 0.5 36.8 ± 0.4 37.1 ± 0.4
Mortality (%) 10 8 10 9
Dex levels (µg/dl, 24 hours) NA 0.9 ± 0.2 0.7 ± 0.1 0.6 ± 0.5
SV-129 mice were treated with dexamethasone (20 mg/kg), RU486 (200 mg/kg), and LY294002 (5 mg/kg). Data are means ± SD (n = 5–12). Dex, dexa-
methasone; RU, RU486; LY, LY294002; MABP, mean arterial blood pressure; Pre, before MCAo; Post, after MCAo; RT, rectal temperature; PaCO2, partial
pressure arterial CO2; PaO2, partial pressure arterial pressure O2; NA, not available.
ciated PI3K activity was blocked by cotreatment with
the PI3K inhibitor LY294002, and the GR antagonist
RU486, suggesting that the effect of dexamethasone
was mediated by GR (Figure 3b).
Furthermore, steroid treatment leads to in vivo acti-
vation of Akt downstream of GR and PI3K, as deter-
mined by Akt kinase activity (upper panels in Figure 3c)
and Akt phosphorylation (lower panels in Figure 3c).
Of note, the transcriptional inhibitor actinomycin D,
in doses reported to inhibit transcriptional responses
to thyroid hormone and dexamethasone in vivo (8, 37),
did not inhibit activation of Akt by corticosteroids.
Thus, activation of the PI3K/Akt axis in vivo does not
require induction of gene expression by GR. These
findings suggest that activation of the PI3K/Akt axis
mediates acute neuroprotection by steroids.
Regulation of vascular tone by corticosteroids. Blood flow is
partially determined by peripheral vascular resistance,
which is negatively regulated by endothelium-derived
NO. To determine the effects of acute administration of
corticosteroids on vascular tone, we measured wall ten-
sion of vascular rings. In vitro, the α-adrenergic agonist
phenylephrine caused dose-dependent contraction of
aortic rings, which can be reversed by acetylcholine
(ACh) in an NO-dependent manner. Cotreatment of
aortic rings with relatively high doses of dexamethasone
reduced aortic-ring wall tension (Figure 4, a and b),
which was reversed by RU486 and LY294002 (Figure
4c). Furthermore, in the absence of eNOS activity, due
to either inhibition by L-NAME or lack of enzyme in
eNOS–/– tissue, baseline contraction was markedly
increased and remained unchanged by dexamethasone
or ACh. These data demonstrate that dexamethasone
exerts rapid, NO-dependent effects and suggest that
vasorelaxation by dexamethasone requires activation of
eNOS through GR and PI3K.
To determine whether corticosteroids actually stim-
ulate eNOS in vivo, mice were treated with dexametha-
sone, and aortic NOS activity was measured by the
enzymatic conversion of the eNOS substrate L -arginine
to L -citrulline (Figure 4d). Dexamethasone treatment
induced a threefold increase in eNOS activity, which
was completely blocked by cotreatment with LY294002
and RU486. In contrast, baseline NOS activity was vir-
tually absent in eNOS–/– mice and remained unrespon-
sive to dexamethasone stimulation (data not shown),
indicating that GR specifically enhances eNOS activi-
ty through a PI3K-dependent mechanism in vivo.
Nontranscriptional actions of GR require high-dose corticos-
teroids. Dexamethasone activates eNOS in human
endothelial cells (ECs) in a nontranscriptional fashion,
which is mediated by the PI3K/Akt pathway (23). Gen-
eration of NO increases intracellular cGMP through
stimulation of guanylate cyclase. To confirm that dexa-
methasone stimulates NO production in ECs from dif-
ferent vascular domains, we measured cGMP levels
(Figure 5a). Dexamethasone increased cGMP levels
about twofold in human umbilical-vein ECs
(HUVECs), an effect which was reversed by LY294002
and the NOS inhibitor L-NAME. Similar effects were
observed in human aortic ECs (HAECs). We also com-
pared the ability of different corticosteroids to activate
eNOS (Figure 5b). All of the tested corticosteroids,
including the endogenous steroid hydrocortisone, were
found to activate eNOS, demonstrating a corticos-
teroid class effect on eNOS activity.
Nontranscriptional activation of PI3K in ECs requires
high doses of dexamethasone (23). Furthermore, only
high-dose steroid treatment provides neuroprotection.
This is in contrast to the genomic responses to steroids.
To further characterize the transcriptional and non-
transcriptional actions of GR, we compared the
dose–response data for eNOS activity with results from
a glucocorticoid-responsive element–dependent (GRE-
dependent) luciferase reporter. Although maximal
induction of eNOS activity required doses of 100 nM to
1 µM of dexamethasone, much lower doses of dexa-
methasone (10 nM) readily induced maximal GRE-
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Figure 3
Activation of PI3K/Akt mediates neuroprotection. (a) Neuroprotec-
tion by dexamethasone is mediated by GR and PI3K. Cerebral infarct
volume after MCAo in response to dexamethasone (20 mg/kg),
RU486 (200 mg/kg) and LY294002 (5 mg/kg, n = 7–11). Vehicle and
dexamethasone groups are identical to those in figure 1a. *P < 0.05
vs. vehicle, **P < 0.05 vs. dexamethasone. RU, RU486; LY,
LY294002. (b) In vivo activation of PI3K by dexamethasone. PI3K
activity from mouse brain tissue immunoprecipitated with GR or p85
antibody. The product of the kinase reaction, PIP3, was visualized by
autoradiography. (c) The left panel shows Akt activity and total Akt
from mouse brain tissue. Mice were treated with vehicle or dexa-
methasone, with or without actinomycin D (ActD) (5 mg/kg),
RU486, or LY294002. The right panel shows P-Akt (S473) and total
Akt from mouse aortae. P, phosphorylation form of the protein. Rep-
resentative experiments are shown.
mediated transcriptional activity. This was reflected in
an approximately 10-fold difference in EC50 values (1.1
nM for GRE-reporter vs. 13 nM for eNOS activity) and
ECmax values (10 nM for GRE-reporter vs. 100 nM for
eNOS activity), as derived from logarithmically trans-
formed curve-fit analysis (Figure 5c).
Consistent with our in vitro findings, the peak serum
dexamethasone level in mice after administration of
neuroprotective doses (20 mg/kg bolus administered
intraperitoneally) was approximately 140 nM (5.5
µg/dl) (Figure 5d). No neuroprotection was observed
when mice were given 0.2 mg/kg of intraperitoneal dex-
amethasone, which gave a peak dexamethasone level of
33 nM (1.3 µg/dl). Together, these findings indicate
that pharmacologic concentrations of corticosteroids
are required for nontranscriptional activation of eNOS
and NO-mediated neuroprotection. Despite such high
concentrations of corticosteroids, the observed effects
are relatively specific since the neuroprotective effects
of corticosteroids are absent in eNOS–/– mice and could
be blocked in vivo by inhibitors of GR and PI3K.
GR mediates the non-nuclear activation of PI3K/Akt by cor-
ticosteroids. To determine on a molecular level whether
GR mediates PI3K activation, we performed studies in
COS7 cells that lack endogenous GR (38). In mock-
transfected cells, treatment with dexamethasone did not
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Figure 4
NO-dependent vasodilation by corti-
costeroids. (a) Wall tension to cumu-
lative concentrations of phenylephrine
in aortic rings incubated with 1 µM
dexamethasone (n ≥ 6). (b) Dose-
dependent effects of dexamethasone
on wall tension in aortic rings pre-
treated with 1 µM phenylephrine 
(n ≥ 4). (c) Wall tension in aortic rings
from wild-type or eNOS–/– mice treat-
ed with phenylephrine and dexa-
methasone or ACh (3µM) with or
without RU486, LY294002, or L-NAME 
(n ≥ 4). (d) Aortic eNOS activity from
wild-type or eNOS–/– mice treated with
vehicle or dexamethasone with or
without RU486 or LY294002 for 2
hours. Three separate experiments
yielded similar results. *P < 0.05. 
Figure 5
Nontranscriptional activation of eNOS by
high-dose corticosteroids. (a) Shown are
cGMP levels in human ECs after dexametha-
sone treatment. The upper panel shows
cGMP levels in HUVECs stimulated with S-
nitrosoglutathione (GSNO, 300 µM) or dex-
amethasone (100 nM) with or without
LY294002 (LY, 30 µM) or L-NAME (1 mM, 
n = 4). The lower panel shows cGMP levels in
HAECs stimulated with dexamethasone with
or without LY294002 (n = 4). Ctrl, control.
*P < 0.05 vs. control. GSNO, S-nitrosoglu-
tathione; LY, LY294002. (b) Effects of 100
nM of dexamethasone, prednisolone, hydro-
cortisone, or triamcinolone acetonide on
eNOS activity in HUVECs (n = 2). Pred, pred-
nisolone; HC, hydrocortisone; TA, triamci-
nolone acetonide. (c) Dose–response effects
of dexamethasone on eNOS activity
(HUVECs, n = 5) and GRE-luciferase activity
(bovine aortic endothelial cells transfected
with pGRE-luc, n = 6). *P < 0.01 vs. control.
(d) Dexamethasone serum levels in mice
after intraperitoneal bolus administration of
low- and high-dose dexamethasone.
activate PI3K or Akt, whereas transfection of human GR
enabled activation of the PI3K/Akt pathway by dexa-
methasone. Furthermore, transfection of a dimerization-
defective GR mutant (A458T), which is unable to bind
DNA and transactivate target genes (38), still activated
the PI3K/Akt pathway in a ligand-dependent manner
(upper panels in Figure 6a). These results suggest a non-
transcriptional mechanism of PI3K/Akt activation, since
GR mutant A458T was unable to induce significant
transcriptional activity (lower panel in Figure 6a).
Nontranscriptional activation of PI3K was further
evaluated in mouse embryonic fibroblasts (MEFs) from
genetically modified mice (Figure 6b). While dexa-
methasone did not activate Akt in GR–/– MEFs, activa-
tion was readily observed in wild-type MEFs, expressing
endogenous levels of GR, and in cells with a dimeriza-
tion-defective GR (GRdim) that renders GR unable to
bind to DNA and induce gene expression (5). These
results indicate that GR is required for nontranscrip-
tional activation of PI3K and downstream effectors.
These findings also suggest specific recruitment of PI3K
to GR. Indeed, we have recently described the associa-
tion of GR with the p85 α regulatory subunit of PI3K in
a ligand-dependent manner (23). Corticosteroids can
bind to and activate the mineralocorticoid receptor
(MR). To determine whether the nontranscriptional
effects of dexamethasone were specific
for GR activation, PI3K activity associ-
ated with different steroid receptors was
examined in HUVECs (Figure 6c).
Treatment with dexamethasone readily
stimulated GR-associated PI3K activity
but did not stimulate association of
PI3K activity with either MR or ERα,
suggesting that PI3K specifically asso-
ciates with ligand-bound GR.
To corroborate the specificity of
high-dose dexamethasone action to-
ward GR, we evaluated Akt activation
in COS7 cells transfected with expres-
sion plasmids for ERα, GRα, or MR
(Figure 6d). Although all receptors were
sufficiently expressed after transfec-
tion, only GR-mediated activation of
Akt by dexamethasone. These findings
suggest that although high doses of
steroids are required for non-nuclear
actions, the effects are nevertheless
specifically mediated by GR.
Discussion
Clinical studies of corticosteroids in
stroke have yielded conflicting results,
which may reflect differences in dosage
regimens, the time to onset of treat-
ment, or the specific clinical condition.
Although several trials in patients with
presumed ischemic stroke have failed
to show a reduction in mortality
(39–42), at least one study has demonstrated a signifi-
cant improvement in functional outcome (43). In
experimental stroke, physiological levels of corticos-
teroids increase the severity of ischemic injury after
global ischemia (44). However, our finding that corti-
costeroids are neuroprotective is consistent with previ-
ous studies showing reduction in stroke size after focal
cerebral ischemia (20–22). Similar to these earlier stud-
ies, we found that pharmacological concentrations of
corticosteroids were required for acute neuroprotec-
tion, whereas lower doses had no effect. It is interesting
to note that this dose–response relationship has also
been observed in spinal cord injury, where low-dose
corticosteroids are not protective, whereas high doses
improve clinical outcome when given within the first 8
hours after injury (45, 46).
Several lines of evidence support the conclusion that
the neuroprotective effect of high-dose steroids is medi-
ated by nontranscriptional activation of eNOS through
the PI3K/Akt pathway. Rapid augmentation of ischemic
CBF and stroke protection by steroids is mediated by
eNOS, since these effects are reversed in the absence of
eNOS. Although neuroprotection is mediated by eNOS,
eNOS expression levels were unchanged by steroid treat-
ment in our studies (i.e., <24 hours), suggesting non-
transcriptional enhancement of eNOS activity. This is in
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Figure 6
Nontranscriptional activation of PI3K by GR. (a) Nontranscriptional activation of PI3K
and Akt kinase by GR: The upper panels show PI3K and Akt kinase assays in COS7 cells
transfected with expression plasmids encoding GRα (GRSB) or dimerization-defective
GR (A458T). Lysates were immunoblotted against GR. The lower panel shows GRE-
reporter activity of COS7 cells cotransfected with either GRSB or A458T expression
plasmid with GRE-luc and stimulated with dexamethasone (100 nM). (b) MEFs
obtained from wild-type, GR–/–, and dimerization-defective GRdim mice were assayed
for Akt activity and expression of GR by Western blotting. (c) Dexamethasone activates
the PI3K/Akt pathway through GR. The upper panel shows immunoprecipitation of
ERα, GR, or MR followed by PI3K assay or immunoblotting against ERα, GR, and MR.
(d) Akt kinase assay in COS7 cells transfected with expression plasmids encoding ER,
GR or MR. Lysates of mock-transfected or receptor-transfected cells were immunoblot-
ted against ER, GR, or MR. Representative experiments are shown; m, mock transfect-
ed. WB, Western blot; P-GSK-3, phospho-GSK-3.
contrast to a previous report showing that longer-term
steroid therapy (i.e., >72 hours) leads to the downregula-
tion of eNOS and an increase in systemic blood pressure
(24). Thus, the beneficial and detrimental effects of
steroid therapy with regard to eNOS expression are, in
part, dependent on the duration and dose of treatment.
In addition, two previous studies suggest that injury from
MCAo could lead to increased eNOS expression (47, 48).
This is in contrast to the findings of our study, which did
not show significant change in eNOS expression in the
brain after MCAo in any treatment group. Differences
between our study and previous studies include the ani-
mal species (i.e., mouse vs. rat), the model of cerebral
ischemia (transient vs. permanent occlusion), and the
method of measuring eNOS expression (real time PCR
vs. immunostaining or semiquantitative RT-PCR).
We found that inhibition of PI3K reversed the bene-
ficial effects of dexamethasone on stroke. Steroids acti-
vate eNOS in vivo and in vitro through the PI3K/Akt
pathway. Although the activation of PI3K by corticos-
teroids requires GR, no GRE-mediated gene transcrip-
tion is necessary for PI3K activation. Instead, activation
of PI3K involves the association of the regulatory p85
subunit of PI3K with GR (23). This non-nuclear effect
of GR is similar to that of the estrogen receptor, which
interacts with and activates PI3K in a ligand-dependent
manner (11). Furthermore, the peak serum dexa-
methasone level in mice treated with neuroprotective
doses corresponded to the in vitro concentration that
maximally stimulated eNOS and PI3K. Together, these
data strongly suggest that nontranscriptional actions
of GR mediate neuroprotection through activation of
PI3K and eNOS, leading to increases in CBF.
In our studies, the non-nuclear and protective actions
of GR require steroid doses at least 10 times as high as
those required for the genomic response by the recep-
tor. Yet, these nongenomic actions are specifically
mediated by GR. Clearly, further studies are needed to
address this discrepancy between transcriptional and
nontranscriptional actions. One might speculate that
activation of PI3K requires so-far-undiscovered adap-
tor molecules bound to a subset of GR that alter the
binding affinity of the receptor for steroids.
Postischemic inflammation and microvascular occlu-
sion contribute to ischemic brain injury, which can be
counteracted by endothelial-derived NO (13, 49). The
inhibitory effects of corticosteroids on endothelial-leuko-
cyte adhesion are mediated by GR (50). However, the
mechanism by which GR inhibits endothelial-leukocyte
interaction is not well understood. By enhancing
endothelial NO production, corticosteroids might inhib-
it platelet aggregation and leukocyte adhesion, thereby
enhancing blood flow. The features of neuroprotection
by GR resemble the role of NO in stroke protection, since
endothelial-derived NO decreases stroke size by improv-
ing regional CBF (14). On the other hand, NO donors
lose their protective efficacy when administered more
than 2 hours after ischemia, an effect that is similar to the
effects of dexamethasone (32, 51). Indeed, the ability of
dexamethasone to induce NO-dependent relaxation in
the mouse aorta probably also contributes to its ability to
increase eNOS activity and CBF in the nonischemic
regions of the brain. This is a novel feature of corticos-
teroids that is distinct from its anti-inflammatory effects.
Protection from ischemia in our model is primarily
dependent on CBF. However, in a different setting, non-
nuclear activation of PI3K and Akt by GR could exert
perfusion-independent protective effects, since Akt
directly inhibits apoptosis in neural tissue and the
myocardium (52, 53). We have recently shown that high-
dose corticosteroids decrease myocardial infarct size
through the PI3K/Akt pathway (23). Although steroid
therapy reduced myocardial infarct size, there was no
change in the area at risk between treatment groups, sug-
gesting additional blood flow–independent effects of
corticosteroids on ischemic myocardium. Indeed, corti-
costeroids can promote survival through an Akt-related
protein kinase, serum- and glucocorticoid-regulated
kinase (SGK) (54, 55). Because SGK is a downstream tar-
get of PI3K (56), the ability of ligand-bound GR to acti-
vate PI3K may, therefore, provide an additional mecha-
nism by which corticosteroids can regulate survival.
The therapeutic use of corticosteroids is limited by
side effects, which occur at relatively low concentra-
tions and are typically associated with long-term treat-
ment. Thus, it appears that these detrimental effects
might be related to the genomic actions of corticos-
teroids. By linking GR to PI3K, the biological and
pharmacological actions of corticosteroids could be
considerably broadened. This would require the devel-
opment of a novel class of drugs that selectively acti-
vate the nontranscriptional actions of GR. Indeed, syn-
thetic compounds that separate specific GR functions,
such as transactivation from transrepression, have
recently been identified (57).
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